Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System lessened its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 11.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 45,230 shares of the medical research company's stock after selling 6,023 shares during the period. New York State Teachers Retirement System owned approximately 0.09% of Charles River Laboratories International worth $8,349,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of CRL. Empirical Finance LLC grew its stake in shares of Charles River Laboratories International by 4.2% in the 3rd quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company's stock worth $258,000 after buying an additional 53 shares in the last quarter. OLD National Bancorp IN grew its position in Charles River Laboratories International by 3.1% in the third quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company's stock worth $392,000 after acquiring an additional 59 shares in the last quarter. Fiduciary Financial Group LLC grew its position in Charles River Laboratories International by 3.9% in the fourth quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company's stock worth $310,000 after acquiring an additional 63 shares in the last quarter. Pinnacle Bancorp Inc. increased its stake in Charles River Laboratories International by 52.0% during the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after acquiring an additional 65 shares during the last quarter. Finally, M&T Bank Corp raised its position in Charles River Laboratories International by 3.4% during the third quarter. M&T Bank Corp now owns 2,001 shares of the medical research company's stock valued at $394,000 after purchasing an additional 66 shares during the period. Hedge funds and other institutional investors own 98.91% of the company's stock.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, CEO James C. Foster acquired 6,075 shares of the company's stock in a transaction dated Thursday, February 20th. The shares were purchased at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the purchase, the chief executive officer now owns 183,639 shares in the company, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, COO Birgit Girshick acquired 1,514 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, February 20th. The stock was acquired at an average cost of $164.63 per share, with a total value of $249,249.82. Following the purchase, the chief operating officer now directly owns 55,058 shares of the company's stock, valued at $9,064,198.54. This represents a 2.83 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Trading Up 0.5 %

Shares of Charles River Laboratories International stock traded up $0.86 on Friday, hitting $163.11. 1,215,815 shares of the company traded hands, compared to its average volume of 1,060,379. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The company has a market cap of $8.34 billion, a PE ratio of 1,087.39, a PEG ratio of 6.77 and a beta of 1.37. The stock's 50 day moving average price is $173.39 and its 200-day moving average price is $188.81. Charles River Laboratories International, Inc. has a 52 week low of $150.79 and a 52 week high of $275.00.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. During the same period in the previous year, the company posted $2.46 EPS. Charles River Laboratories International's revenue was down 1.1% on a year-over-year basis. Equities research analysts predict that Charles River Laboratories International, Inc. will post 9.41 EPS for the current year.

Analyst Upgrades and Downgrades

CRL has been the topic of several analyst reports. UBS Group reissued a "neutral" rating and set a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Evercore ISI boosted their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an "in-line" rating in a research report on Thursday, November 7th. TD Cowen increased their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a research note on Monday, November 11th. Robert W. Baird dropped their price target on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating for the company in a research note on Thursday. Finally, CLSA lowered shares of Charles River Laboratories International from a "hold" rating to an "underperform" rating and set a $164.00 price objective on the stock. in a research report on Monday, November 18th. Three investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $195.71.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).